The psychobiology of the acute schizophrenic episode

International Clinical Psychopharmacology

Volumn 11, Issue SUPPL. 2, 1996, Pages 19-28

  Muller Spahn F ^a   Eich, P ^a   Hock, C ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Apomorphine; Dopamine; Gamma aminobutyric acid; Glutamate; Positive and negative symptoms; Schizophrenia; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID; APOMORPHINE; DOPAMINE; GLUTAMIC ACID; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN;

CONFERENCE PAPER; DOPAMINERGIC SYSTEM; HUMAN; PRIORITY JOURNAL; PSYCHOBIOLOGY; SCHIZOPHRENIA; SUBCUTANEOUS DRUG ADMINISTRATION; SYMPTOMATOLOGY;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; AUTOPSY; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROSECRETORY SYSTEMS; NEUROTRANSMITTER AGENTS; RADIONUCLIDE IMAGING; RECEPTORS, DOPAMINE; SCHIZOPHRENIA;

EID: 0029949319     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199605002-00004     Document Type: Conference Paper

References (55)

1. Akbarian S, Viñuela A, Kim J, Potkin S, Bunney WE Jr, Jones E (1993) Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 50:178-187.
2. Akbarian S, Kim J, Potkin S, et al. (1995) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 52:258-266.
3. Altshuler L, Casanova M, Goldberg TE, et al. (1990) The hippocampus and parahippocampus in schizophrenic, suicide and control brains. Arch Gen Psychiatry 47:1029-1034.
4. Andreasen N (1994) Neuroimaging assessment of cognitive disorders. J Clin Psychiatry 55 (suppl 11):3-4.
5. Andreasen N, Swayze V, Flaum M, Yates W, Arndt S, McChesney C (1990) Ventricular enlargement in schizophrenia evaluated with computed tomographic scanning. Arch Gen Psychiatry 47:1008-1015.
6. Andreasen N, Rezai K, Alliger R, et al. (1992) Hypofrontality in neuroleptic-naive patients and inpatients with chronic schizophrenia. Arch Gen Psychiatry 49:943-958.
7. Andreasen N, Arndt S, Swayze V, et al. (1991) Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 266:294-298.
8. Arnold SE, Hyman BJ, Van Hoesen GW, et al. (1991) Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry 48:625-632.
9. Benes FM, McSparren J, Bird ED, Sangiovanni JP, Vincent SL (1991) Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 48:996-1001.
10. Berman K, Doran A, Pickar D, Weinbgerger D (1993) Is the mechanism of prefrontal hypofunction in depression the same as in schizophrenia? Br J Psychiatry 162:183-192.
11. Bondy B, Ackenheil M, Birzle W, Elbers R, Fröhler M (1984) Catecholamines and their receptors in blood: evidence for alterations in schizophrenia. Biol Psychiatry 19:1377-1393.
12. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13:177-213.
13. Buchsbaum M, Maier R, Potkin S, et al. (1992) Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry 49:935-942.
14. Buchsbaum M, Someya T, Teng C, et al. (1996) PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiatry 153:191-199.
15. Cannon T, Marco E (1994) Structural brain abnormalities as indicators of vulnerability to schizophrenia. Schizophr Bull 20:89-102.
16. Carlsson A (1988) The current status of dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179-186.
17. Chang W, Chen T, Lee C, Hung J, Hu W, Yeh E (1988) Plasma homovanillic acid levels and subtyping of schizophrenia. Psychiatry Res 23:239-244.
18. Cleghorn J, Garnett E, Nahmias C, Brown G, et al. (1990) Regional brain metabolism during auditory hallucinations in chronic schizophrenia. Br J Psychiatry 157:562-570.
19. Davidson M, Kahn R, Knott P, et al. (1991) Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry 48:910-913.
20. Davilla R, Manero E, Zumarraga M, Andia I, Schweitzer J, Friedhoff A (1988) Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry 5:564-567.
21. Davis K, Davidson M, Mohs R, et al. (1985) Plasma homovanillic acid concentration and the severity of schizophrenic illness. Science 227:1601-1602.
22. Davis KL, Kahn R, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474-1486.
23. Dolan R, Bench C, Liddle P, et al. (1993) Dorsolateral prefrontal cortex dysfunction in the major psychoses: symptom or disease specificity? J Neurol Neurosurg Psychiatry 56:1290-1294.
24. Elkis H, Friedman L, Wise A, Meltzer H (1995) Meta-analyses of studies of ventricular enlargement and cortical prominence in mood disorders. Arch Gen Psychiatry 52:735-746.
25. Falkai P, Bogerts B (1986) Cell loss in the hippocampus of schizophrenics. Eur Arch Psychiatry Neurol Sci 263: 154-161.
26. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538-544.
27. Feinberg I (1983) Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J Psychiatr Res 17:319-338.
28. Ferrier I, Johnstone E, Crow T (1984) Hormonal effects of apomorphine in schizophrenics. Br J Psychiatry 144:349-357.
29. Fleminger S, Jenner P, Marsden C (1982) Are dopamine receptors present on human lymphocytes? J Pharm Pharmacol 34: 658-663.
30. Frith C, Friston K, Herold S, et al. (1995) Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. Br J Psychiatry 167:343-349.
31. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsitivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24.
32. 3H)-spiperone binding to peripheral blood lymphocytes from neuroleptic responsive and nonresponsive schizophrenic patients. Biol Psychiatry 27: 1327-1330.
33. Gur R, Mozley D, Resnick S, et al. (1995) Resting cerebral glucose metabolism in first episode and previously treated patients with schizophrenia relates to clinical features. Arch Gen Psychiatry 52:657-667.
34. Jeste DV, Lohr JB (1989) Hippocampal pathologic findings in schizophrenia: a morphometric study. Arch Gen Psychiatry 46:1019-1024.
35. Krishnan K, Boyko O, Figiel G (1995) Imaging in psychiatric disorders. In Neuroimaging. Edited by Greenberg J. New York: McGraw-Hill; pp 227-250.
36. 3H)-spiperidon binding on lymphocytes: changes in two different groups of schizophrenic patients and effect on neuroleptic treatment. Life Sci 32:249-255.
37. Liddle PF, Friston K, Frith C, et al. (1992) Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 160:179-186.
38. Lieberman J, Koreen A (1993) Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 19:371-429.
39. Mazure C, Nelson J, Jatlow P, Bowers M (1991) Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol Psychiatry 30:475-482.
40. Müller-Spann F (1991) Neuroendokrinologie und Schizophrenieforschung. Monographien aus dem Gesamtgebiete der Psychiatrie, Bd. 64. Berlin: Springer.
41. Müller-Spahn F, Hock C, Kurtz G (1994) Neurochemical and neuroendocrine measures and prediction of outcome to neuroleptic therapy. In Prediction of Neuroleptic Treatment Outcome in Schizophrenia. Edited by Gaebel W, Awad A. New York: Springer; pp 111-122.
42. Nopoulos P, Torres I, Flaum M, Andreasen N, Erhardt J, Yuh W (1995) Brain morphology in first-episode schizophrenia. Am J Psychiatry 152:1721-1723.
43. Olney J, Farber N (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
44. Pakkenberg B (1987) Postmortem study of chronic schizophrenic brains. Br J Psychiatry 151:744-752.
45. Pakkenberg B (1990) Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry 47: 1023-1028.
46. Paulman R, Devous M, Gregory R, et al. (1990) Hypofrontality and cognitive impairment in schizophrenia: dynamic single-photon tomography and neuropsychological assessment of schizophrenic brain function. Biol Psychiatry 27:377-399.
47. Pickar D, Labarca R, Doran A, et al. (1986) Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch Gen Psychiatry 4:669-679.
48. 4 receptors elevated in schizophrenia. Nature 365:441-445.
49. Selemon LD, Rajkowska G, Goldman-Rakic PS (1995) Abnormally high neuronal density in the schizophrenic cortex. Arch Gen Psychiatry 52:805-818.
50. Sharma R, Javaid J, Janicak P, Comaty J, Davis J, Faull K (1988) Effect of trifluoperazine on CSF and plasma HVA levels in schizophrenic subjects. Am J Psychiatry 145:1480-1481.
51. Suddath R, Christison G, Torrey E, Casanova M, Weinberger D (1990) Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N Engl J Med 322: 789-794.
52. Williamson P, Pelz D, Merskey H, Morrison S, Conlon P (1991) Correlation of negative symptoms in schizophrenia with frontal lobe parameters on magnetic resonance imaging. Br J Psychiatry 159:130-134.
53. Wolkin A, Sanfilipo M, Wolf A, Angrist B, Brodie J, Rotrosen J (1992) Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 49:959-965.
54. Wyatt R (1996) Neurodevelopmental abnormalities and schizophrenia. Arch Gen Psychiatry 53:11-15.
55. Zemlan F, Hirschowitz J, Garver D (1986) Relation of clinical symptoms to apomorphine stimulated growth hormone release in mood-incongruent psychotic patients. Arch Gen Psychiatry 43:1162-1167.